Takeda presents late-breaking data from phase 2b study of mezagitamab, demonstrating potential to transform treatment of primary immune thrombocytopenia

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today presented positive results from its phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (tak-079) in patients with persistent or chronic primary immune thrombocytopenia (itp), a rare immune-mediated bleeding disorder. itp is characterized by the accelerated destruction of platelets in blood, resulting in a decreased platelet count and an inc.
TAK Ratings Summary
TAK Quant Ranking